PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Heart failure - what's new and what's changed?

Abstract Physicians responsible for the care of patients with heart failure due to left ventricular systolic dysfunction have access to a broad range of evidence-based treatments that prolong life and reduce symptoms. In spite of the significant progress made over the last four decades, there is an ongoing need for novel therapies to treat a condition that is associated with stubbornly high morbidity and mortality. In this article, we discuss the findings of SERVE-HF, a randomised controlled trial of adaptive servo-ventilation in patients with left ventricular systolic dysfunction, as well as EMPA-REG, a study of the effects of a novel diabetic agent that may be of greater interest to heart failure specialists than diabetologists. We also examine further analyses of the groundbreaking PARADIGM-HF trial, which attempt to answer some of the unresolved questions from the original study of the first combined angiotensin-receptor blocker and neprilysin inhibitor, sacubitril valsartan. The recently published National Institute for Health and Care Excellence guidelines for the management of acute heart failure and plans to introduce best practice tariffs bring into focus the need for well-organised, multidisciplinary care. We discuss the challenges involved in developing and delivering a specialist service that meets the needs of a growing population of patients living with heart failure.
PMID
Related Publications

Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure.

Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.

Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.

Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.

Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.

Authors

Mayor MeshTerms
Keywords

Adaptive servo-ventilation

angiotensin receptor neprilysin inhibitors

clinical trials

diabetes mellitus

heart failure

organisation of care

Journal Title clinical medicine (london, england)
Publication Year Start




PMID- 27956439
OWN - NLM
STAT- In-Process
DA  - 20161213
LR  - 20170208
IS  - 1473-4893 (Electronic)
IS  - 1470-2118 (Linking)
VI  - 16
IP  - Suppl 6
DP  - 2016 Dec
TI  - Heart failure - what's new and what's changed?
PG  - s37-s42
AB  - Physicians responsible for the care of patients with heart failure due to left
      ventricular systolic dysfunction have access to a broad range of evidence-based
      treatments that prolong life and reduce symptoms. In spite of the significant
      progress made over the last four decades, there is an ongoing need for novel
      therapies to treat a condition that is associated with stubbornly high morbidity 
      and mortality. In this article, we discuss the findings of SERVE-HF, a randomised
      controlled trial of adaptive servo-ventilation in patients with left ventricular 
      systolic dysfunction, as well as EMPA-REG, a study of the effects of a novel
      diabetic agent that may be of greater interest to heart failure specialists than 
      diabetologists. We also examine further analyses of the groundbreaking
      PARADIGM-HF trial, which attempt to answer some of the unresolved questions from 
      the original study of the first combined angiotensin-receptor blocker and
      neprilysin inhibitor, sacubitril valsartan. The recently published National
      Institute for Health and Care Excellence guidelines for the management of acute
      heart failure and plans to introduce best practice tariffs bring into focus the
      need for well-organised, multidisciplinary care. We discuss the challenges
      involved in developing and delivering a specialist service that meets the needs
      of a growing population of patients living with heart failure.
CI  - (c) Royal College of Physicians 2016. All rights reserved.
FAU - Callan, Paul D
AU  - Callan PD
AD  - Advanced Heart Failure and Cardiac Transplantation, University Hospital of South 
      Manchester, Manchester, UK [email protected]
FAU - Clark, Andrew L
AU  - Clark AL
AD  - Hull York Medical School and honorary consultant cardiologist, Hull and East
      Yorkshire NHS Hospitals Trust, York, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Med (Lond)
JT  - Clinical medicine (London, England)
JID - 101092853
OTO - NOTNLM
OT  - Adaptive servo-ventilation
OT  - angiotensin receptor neprilysin inhibitors
OT  - clinical trials
OT  - diabetes mellitus
OT  - heart failure
OT  - organisation of care
EDAT- 2016/12/14 06:00
MHDA- 2016/12/14 06:00
CRDT- 2016/12/14 06:00
AID - 16/Suppl_6/s37 [pii]
AID - 10.7861/clinmedicine.16-6-s37 [doi]
PST - ppublish
SO  - Clin Med (Lond). 2016 Dec;16(Suppl 6):s37-s42.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>